The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,914.00
Bid: 1,912.00
Ask: 1,915.00
Change: -10.00 (-0.52%)
Spread: 3.00 (0.157%)
Open: 1,902.00
High: 1,916.00
Low: 1,902.00
Prev. Close: 1,924.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE: MARKET COMMENT: Stocks Down Ahead Of Weekend Bank Stress Tests

Fri, 24th Oct 2014 10:08

LONDON (Alliance News) - The major UK stock indices are trading modestly lower Friday as investors exercise caution ahead of a weekend that brings the results of the EU bank stress tests, and concerns remain about the health of the wider global economy and the spread of the Ebola virus.

By mid-morning Friday, the FTSE 100 is down 0.2% at 6,405.25, the FTSE 250 is fractionally lower at 15,130.00, while the AIM All-Share is fractionally higher at 709.11.

Major European equity markets are also a little lower, with the French CAC 40 and the German DAX both down 0.3%.

The UK economy grew by 0.7% in the third quarter, according to the initial estimate from the Office for National Statistics Friday. That's a slow-down from the 0.9% growth recorded in the second quarter, but in line with expectations. On an annual basis, the ONS said growth was 3.0%, down from 3.2% in the second quarter, also in line with expectations.

The data did little to boost the stock market, but did provide a small boost to to the pound which pushed to intra-day highs of USD1.6057 and EUR1.2687.

The results of the EU Asset Quality Review, or bank stress tests, will be released on Sunday. Capital hoarding by the banks ahead of the tests has for months been widely blamed as part of the reason behind a lack of lending in the Eurozone. The possibility that some banks have failed is leading to caution in the markets, after a report from Spanish news agency Efe earlier in the week that 11 banks have failed. Bloomberg reported that Irish bank Permanent TSB Group Holdings PLC failed the stress tests under the adverse scenario being assessed by regulators, citing a person with knowledge of the matter.

Before the European markets opened Friday, official data from China showed a 1.3% slowdown in the housing market there in September, with almost all major cities experiencing a fall in prices. Evidence of a slowdown in the Chinese economy almost always has a negative effect on global equity markets.

Investors are also contending with concerns over the continued spread of Ebola, after another case of the deadly virus was confirmed in New York. A doctor returning from West Africa is the latest American victim.

BT Group is the worst performing blue chip stock in London, down 2.3% after Morgan Stanley downgraded the stock to Underweight, from Equal-weight.

Publishing group Pearson is down 2.2% after announcing that its Chief Financial officer Robin Freestone will step down by the end of 2015 to explore other interests. Pearson reported a 1% rise in sales over the first nine months of the year at constant exchange rates and reiterated its full year guidance. Numis analyst Gareth Davies said that Freestone has been a strong CFO for the group and will be a loss.

Tesco is a heavy faller once again, down 1.3% at 169p. After confirming Thursday that the error in its first half accounts was bigger than initially thought, the troubled supermarket suffered a negative note from JP Morgan Friday. The bank cut its price target on the stock to 145p from 165p, reiterating an underweight rating.

FTSE 250-listed bank TSB Group is performing well, up 1.5%, after reporting a solid set of third quarter results. TSB said it made GBP33.1 million pretax profit in the third quarter, up from GBP25.7 million in the previous three months. There was no consensus expectations for the quarterly results, but Jefferies says it would categorise the numbers as "fine". Lloyds Banking Group, which still owns 50% of TSB, is up 0.7%.

Electronics group Spectris is up 3.5% despite saying its full year results will be a little below consensus. The instrumentation and controls company said sales in its third quarter to end-September fell 5%, as growth contributed by acquisitions of 2% was offset by the strength of sterling, which had a negative effect of 7%. Jefferies says that a heavy share price fall in recent months had priced in an even worse outcome, and the actual result was better than feared.

Pets At Home is up 3.3% after reporting sales growth of 4.2% in both the second quarter and first half, in line with expectations.

Hikma Pharmaceuticals is under pressure at the other end of the FTSE 250, down 5.6%, after saying it received a warning letter from the US Food and Drug Administration related to a March inspection of its manufacturing facility in Portugal, although it stressed it does not believe this will impact its financial guidance for the full year. In the letter, the FDA raised issues related to investigations and environmental monitoring at the the facility, Hikma said.

Still to come Friday, Irish drug maker Shire will publish its third quarter results midday.

The US technology sector will also be in focus when Wall Street opens after both Amazon.com Inc and Microsoft Corp reported results after the closing bell on Thursday. Amazon reported a net loss of USD437 million for the third quarter, compared with a USD41 million loss a year earlier. The stock is more than 10% lower in pre-market. Microsoft, on the other hand, is up 3.0% in pre-market after reporting a profit of USD4.5 billion in the third quarter, down from USD5.2 billion a year earlier but beating Wall Street expectations.

US stock markets are currently set to follow Europe fractionally lower, with DJIA futures flat, but the S&P 500 pointing down 0.1%, and the Nasdaq Composite pointing down 0.2%.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
1 Mar 2023 09:52

LONDON BROKER RATINGS: Canaccord says sell Future; Investec likes RWS

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
27 Feb 2023 09:38

Berenberg raises target price on Hikma Pharmaceuticals

(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,440.0p to 1,740.0p on Monday on the back of the group's recent trading update.

Read more
27 Feb 2023 09:26

LONDON BROKER RATINGS: Citi cuts Quilter to 'sell'; Goldman likes GSK

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
24 Feb 2023 09:37

LONDON BROKER RATINGS: SocGen cuts Burberry; BofA cuts WH Smith

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
23 Feb 2023 09:54

Hikma Pharmaceuticals profit halves in 2022 on Generics impairment

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported a dip in annual revenue for 2022, as profit tumbled due to high inflation and adjustments regarding expectations for its Generics business.

Read more
23 Feb 2023 09:02

LONDON MARKET OPEN: Mixed open in London; Rolls-Royce up, Mondi down

(Alliance News) - Stock prices in London opened mixed on Thursday, with large-cap indices underperforming amid mixed corporate earnings.

Read more
23 Feb 2023 07:59

Competition in generics sees Hikma Pharmaceuticals's profits decline by a tenth

(Sharecast News) - Hikma Pharmaceuticals posted lower full-year profits as stiff competition in generics saw its top line growth flatten out.

Read more
23 Feb 2023 07:56

LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth

(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.

Read more
22 Feb 2023 21:50

Hikma accuses Amarin of suppressing generic versions of heart pill

Hikma claims Amarin used exclusive agreements with suppliers to frustrate generic rivals

*

Read more
16 Feb 2023 15:49

UK earnings, trading statements calendar - next 7 days

Friday 17 February 
Allianz Technology Trust PLCFull Year Results
Kingspan Group PLCFull Year Results
NatWest Group PLCFull Year Results
Pod Point Group Holdings PLCFull Year Results
Segro PLCFull Year Results
Monday 20 February 
Bank of Cyprus Holdings PLCFull Year Results
Georgia Capital PLCFull Year Results
Goldplat PLCFull Year Results (TBC)
LungLife AI IncFull Year Results
Tristel PLCHalf Year Results
Wilmington PLCHalf Year Results
Tuesday 21 February 
Antofagasta PLCFull Year Results
BHP Group LtdHalf Year Results
Blancco Technology Group PLCHalf Year Results
Finsbury Food Group PLCHalf Year Results
HSBC Holdings PLCFull Year Results
InterContinental Hotels Group PLCFull Year Results
Safestore Holdings PLCTrading Statement
Smith & Nephew PLCFull Year Results
Springfield Properties PLCHalf Year Results
Sylvania Platinum LtdHalf Year Results
Trifast PLCTrading Statement
Wednesday 22 February 
Avingtrans PLCHalf Year Results
City of London Investment Group PLCHalf Year Results
Conduit Holdings LtdFull Year Results
Liberty Global PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Primary Health Properties PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
Rio Tinto PLCFull Year Results
Synectics PLCFull Year Results
TBC Bank Group PLCFull Year Results
Transense Technologies PLCHalf Year Results
Thursday 23 February 
Anglo American PLCFull Year Results
Arbuthnot Banking Group PLCTrading Statement
BAE Systems PLCFull Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Drax Group PLCFull Year Results
Driver Group PLCFull Year Results
Genus PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Made Tech Group PLCHalf Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
Versarien PLCFull Year Results
WPP PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
25 Jan 2023 09:33

LONDON BROKER RATINGS: Goldman likes UK banks; HSBC cuts Dr Martens

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
18 Jan 2023 15:07

Director dealings: Hikma Pharmaceuticals director snaps up shares

(Sharecast News) - Hikma Pharmaceuticals revealed on Wednesday that non-executive director Deneen Vojta had acquired 1,000 ordinary shares in the FTSE 250-listed drugmaker.

Read more
12 Jan 2023 17:55

Arecor transfers AT307 drug to Hikma for development, regains AT282

(Alliance News) - Arecor Therapeutics PLC on Thursday said it transferred development activities for the ready-to-use injectable medicine AT307 to Hikma Pharmaceuticals PLC, and regained rights on AT282 after a product portfolio review.

Read more
3 Jan 2023 17:31

FTSE 100 ends first trading day of 2023 on upbeat note

FTSE 100 up 1.4%, FTSE 250 adds 1.5%

*

Read more
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.